Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-IMPACT: Durvalumab and mFOLFIRINOX in Resectable Pancreatic Cancer
NCT06094140Phase 2Active, not recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Proportion of patients receiving at least 80% of planned neoadjuvant treatment at 3 months. Started May 2022; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06094140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094140.